Company CVAbout Laurus Labs Ltd 
Laurus Labs Ltd
Mid Cap
Pharmaceuticals & Biotechnology
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others.
Company Coordinates
Company Details
Plot No 21 Jawaharlal Nehru, Pharma City Parawada Visakhapatnam Andhra Pradesh : 531021
Registrar Details
Karvy Computershare Pvt Ltd., Karvy Selenium, Tower-B Plot No 31 & 32, Survey No 116/22, 115/24, 115/25, Financial District, Nanakramguda, Serilingampally, Mandal Ranga Reddy Dist, Hyderabad
Capital StructureCapital Structure
Present Equity Capital
INR 107.83 Cr
Number of Shares
53.91 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
28-May-2024
53.91
107.83
161349
2
Issued under ESOP Scheme
08-Dec-2023
53.9
107.79
314933
2
Issued under ESOP Scheme
17-Dec-2022
53.87
107.73
1291590
2
Issued under ESOP Scheme
20-Dec-2021
53.74
107.47
756950
2
Issued under ESOP Scheme
22-Dec-2020
53.66
107.32
607390
2
Issued under ESOP Scheme
29-Sep-2020
53.6
107.20
428795996
2
Stock Split
16-Jul-2020
10.72
107.20
278500
10
Issued under ESOP Scheme
24-Sep-2019
10.69
106.91
477750
10
Issued under ESOP Scheme
24-Sep-2019
10.69
106.91
477750
10
Issued under ESOP Scheme
20-Sep-2018
10.63
106.28
248250
10
ESOP
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Non Institution
Pledged Promoter Holdings
2.6853
Mutual Funds
Held by 33 Schemes (7.78%)
FIIs
Held by 217 FIIs (25.7%)
Promoter with highest holding
M/s. Nsn Holdings (represented By Its Managing Partner, Dr. Satyanarayana Chava) (22.99%)
Highest Public shareholder
New World Fund Inc (6.49%)
Individual Investors Holdings
23.12%
Board of Directors
Management
Designation
Remuneration
M V G Rao
Chairman & Independent Directo
25.0 lacs
CHAVA SATYANARAYANA
Executive Director & CEO
18.64 cr
VENKATA RAVI KUMAR VANTARAM
Executive Director & CFO
4.97 cr
Aruna Bhinge
Independent Non Exe. Director
26.0 lacs
Rajesh Koshy Chandy
Independent Non Exe. Director
38.59 lacs
Ravindranath Kancherla
Independent Non Exe. Director
24.5 lacs
Venkata Lakshmana Rao Chunduru
Executive Director
3.3 cr
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Packing Materials
82.67
0%
Packing Materials
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
API and Intermediates
2,074.07
92.75%
Contract Research Services
84.48
3.78%
Other Operating Revenue - Export and other Incentives
26.54
1.19%
API and Intermediates
API and Intermediates
Contract Research Services
Contract Research Services
Other Operating Revenue - Export and other Incentives
Other Operating Revenue - Export and other Incentives
Stock DNARevenue and Profits:
Net Sales:
1,653 Cr
(Quarterly Results - Sep 2025)
Net Profit:
195 Cr
Pharmaceuticals & Biotechnology
INR 54,466 Cr (Mid Cap)
80.00
34
0.16%
0.45
14.23%
11.37
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
